Inven2 makes a difference by turning research into services and products that benefit society. In 2016, we clearly saw the value of this work, which we carry out on behalf of the University of Oslo and all the health trusts in the South-Eastern Regional Health Authority. The value can be measured in monetary terms, but, even more important, in the form of ground-breaking new treatments and medical technology equipment. You can read more about this in the ‘success stories’ section.
Read more
new ideas
new companies established
new license agreements
new patent applications
new clinical studies
ongoing clinical studies
billion NOK combined value of portfolio companies
million NOK to
new research
million NOK in private capital raised
Making a difference by transforming knowledge into products and services for the benefit of society.
Research and knowledge are the key to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from all over Norway report ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products and services that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since our ecosystem is especially strong in that field.
Another important task we perform is to administer agreements on clinical trials on behalf of the hospitals in our region. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. It has 32 employees.
Last year was an exciting year for Inven2 and the companies in our portfolio. See a selection of this year’s success stories.
Inven2 is part of a vital, ever-growing ecosystem in research and development. The area near Inven2’s premises in Oslo Science Park is home to a number of clusters and incubators, as well as the University of Oslo and Oslo University Hospital. This ecosystem is especially strong in the field of life science. This is reflected by the fact that about two-thirds of Inven2’s projects involve developing new therapies and medical technology equipment that patients worldwide can benefit from.
We are proud to co-organise the Cutting Edge Festival, Norway’s biggest science and technology event, where we present the latest in science, technology and innovation together with our partners Oslotech and the University of Oslo.
Visitors
Talkes
Workshops
Debates
Stages
Exhibitors
A shortage of capital in the early phase is a well-known challenge for start-ups. To help with this problem, the Norwegian Government allocated pre-seed capital funding in the national budget in 2015 and 2016. Nine enterprises in Inven2’s network were granted NOK 10 million in support, which was then matched by NOK 50 million in private capital.
Read more
Inven2 works to promote innovation and entrepreneurship among students. Our most important tool is the entrepreneur competition Inven2Start.
Read moreThe companies in our portfolio are worth almost NOK 8 billion and raised NOK 923 million in private capital in 2016.
In brief, we have expertise and provide services relating to business development, patenting, communication, licensing, starting a business and obtaining funding. We also have a large network of partners in Norway and abroad.
Report invention
Norsk
